<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:35:29Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/33573" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/33573</identifier><datestamp>2026-09-22T07:12:40Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">D'Souza, Rohan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Woolley, Emma</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department">Health Care Research Methods</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2026-09-21T14:35:54Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2026</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/11375/33573</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/7671</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Background: Low molecular weight heparin (LMWH) is a first-line anticoagulant for the
treatment and prevention of venous thromboembolism during pregnancy and
postpartum, a leading cause of maternal mortality and morbidity in high-income settings.
This study sought to explore healthcare professionals’ (HCPs) perspectives on access
to LMWH during pregnancy and postpartum in Ontario, Canada, where prior research
suggests ongoing accessibility concerns in the general population.
Methods: A qualitative descriptive study was conducted using semi-structured
interviews with Ontario HCPs caring for people who require LMWH during pregnancy
and postpartum. Interviews were audio-recorded, transcribed verbatim, and analyzed
using rapid qualitative analysis.
Results: Seventeen HCPs (physicians, nurses, pharmacists) from thirteen Ontario
facilities were interviewed. Participants identified multi-level factors influencing access
to LMWH across key access stages, including risk identification, access to specialist
care, adjudication, cost navigation, pharmacy access, and adherence. Factors related to
adjudication and cost navigation were among the most emphasized by HCPs, who
reported barriers associated with insufficient and delayed public coverage, and reliance
on workarounds, such as compassionate supply programs, samples, and broad
application of limited-use criteria. Participants also highlighted geographic barriers to
specialized perinatal care, limited availability in pharmacies, variability in HCPs’
awareness of workarounds, and factors influencing adherence, including patients’ risk
perception, and their willingness and capacity to overcome the logistical challenges
associated with self-injection during pregnancy and postpartum.
Conclusions: Access to LMWH during pregnancy and postpartum is influenced by
factors across system-, facility, HCP-, and patient levels. Findings from this qualitative
descriptive study reveal opportunities to improve equitable access to essential
medications during pregnancy and postpartum, and may inform clinical practice, policy,
and public health efforts.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree">Master of Public Health (MPH)</dim:field>
   <dim:field mdschema="dc" element="subject">Medication access</dim:field>
   <dim:field mdschema="dc" element="subject">drug policy</dim:field>
   <dim:field mdschema="dc" element="subject">pregnancy and postpartum</dim:field>
   <dim:field mdschema="dc" element="title">Healthcare Professional Perspectives on Access to Low Molecular Weight Heparin During Pregnancy and Postpartum: A Qualitative Description of Drug Access and Health Equity in Ontario</dim:field>
   <dim:field mdschema="dc" element="type" lang="en">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>